Novo Nordisk to Acquire Dicerna for ~$3.3B

Share this


Novo Nordisk to Acquire Dicerna for ~$3.3B


  • Novo Nordisk to acquire all outstanding shares of Dicerna common stock for $38.25/share in cash making a total equity value of ~$3.3B representing a premium of 80% to Dicerna's closing price on Nov 17, 2021. The transaction is expected to close in the Q4'21
  • The acquisition will utilize Dicerna's GalXC technology platform to expand the Novo Nordisk's research within RNAi therapeutics. This acquisition supports Novo Nordisk's strategy of developing and apply a range of technology platforms across all therapeutic areas
  • Novo Nordisk is expected to initiate the clinical development of RNAi therapeutic in 2022. In 2019, Novo Nordisk entered a research collaboration with Dicerna to discover and develop RNAi therapies for liver-related cardio-metabolic diseases

Ref: Novo Nordisk | Image: Dicerna 

Click here to­ read the full press release 


This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions